Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
3.4
Journals
Vaccines
Special Issues
Cancer Vaccines: 4th Edition
share announcement

Cancer Vaccines: 4th Edition

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccination Against Cancer and Chronic Diseases".

Deadline for manuscript submissions: 31 March 2026 | Viewed by 1962

Special Issue Editor

Dr. So Young Yoo

E-Mail Website
Guest Editor
BIO-IT Foundry Technology Institute, Pusan National University, Busan, Republic of Korea
Interests: cancer immunotherapy; virotherapy; regenerative therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Vaccines have saved millions of people from infectious diseases. Despite advances in immunology and medicine, developing vaccines against cancers is still a challenge for researchers. Recent studies have shown some remarkable steps toward successful development. Vaccines are used to induce antitumor immunity through specific tumor-associated antigens. Cancer cells also express normal cell antigens, which limits the development of therapeutic vaccines. Targeting tumor-associated antigens and neoantigens on cancer cells is widely used to stimulate effective antitumor immunity in therapeutic vaccine approaches. In addition, various adjuvants have been used to enhance antitumor immunity with these targeting approaches. The tumor microenvironment comprises various immune cells and suppresses tumor antigen expression. In order to target the tumor microenvironment, combined therapeutic approaches using oncolytic viruses, immune checkpoint inhibitors, and adoptive T-cell therapy have been widely employed. This Special Issue will specially focus on cancer vaccine development. Therefore, we welcome research articles as well as review articles, which would not only provide immense knowledge in these topics but also lead to new directions in cancer vaccine research.

Dr. So Young Yoo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer immunotherapy
  • therapeutic vaccine
  • tumor-associated antigens
  • neoantigens
  • adjuvant
  • tumor microenvironment
  • oncolytic viruses
  • immune checkpoint inhibitors

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 3373 KB  
Article
ImmuniT Platform for Improved Neoantigen Prediction in Lung Cancer
by Stephanie J. Hachey, Alexander G. Forsythe, Hari B. Keshava and Christopher C. W. Hughes
Vaccines 2025, 13(9), 921; https://doi.org/10.3390/vaccines13090921 - 29 Aug 2025
Abstract
Background: Lung cancer remains the leading cause of cancer-related mortality, with many patients responding poorly to immunotherapy due to limited tumor recognition. Neoantigen-based strategies offer a promising solution, but current discovery methods often miss key targets, particularly those with low or heterogeneous expression. [...] Read more.
Background: Lung cancer remains the leading cause of cancer-related mortality, with many patients responding poorly to immunotherapy due to limited tumor recognition. Neoantigen-based strategies offer a promising solution, but current discovery methods often miss key targets, particularly those with low or heterogeneous expression. To address this, we developed ImmuniT, a three-phase platform for enhanced neoantigen discovery and validation. Methods: Under an IRB-approved protocol, patients with lung cancer consented to tumor collection for ex vivo processing to modulate antigen expression. Autologous T cells from matched blood were co-cultured with treated cancer cells to expand tumor-reactive populations. The nextneopi pipeline integrated mutational, transcriptomic, and HLA data to predict candidate neoantigens, which were validated using MHCepitope tetramer staining. Results: In five patient samples, ImmuniT identified a broader spectrum of neoantigens and induced stronger T cell activation in vitro compared to conventional approaches. Notably, in one case, two neoantigens missed by standard methods were confirmed to elicit tumor-specific T cell responses in both the tumor-infiltrating and peripheral compartments. Conclusions: These findings highlight ImmuniT’s potential to expand the repertoire of actionable tumor antigens and improve personalized immunotherapy strategies, particularly for patients with limited response to existing treatments. Full article
(This article belongs to the Special Issue Cancer Vaccines: 4th Edition)
►▼ Show Figures

Figure 1

Review

Jump to: Research

40 pages, 2128 KB  
Review
Therapeutic Colorectal Cancer Vaccines: Emerging Modalities and Translational Opportunities
by Palaniyandi Muthukutty, Hyun Young Woo and So Young Yoo
Vaccines 2025, 13(7), 689; https://doi.org/10.3390/vaccines13070689 - 26 Jun 2025
Viewed by 1482
Abstract
Therapeutic vaccines offer a targeted approach to enhancing anti-tumor immunity with minimal systemic toxicity. Despite advancements in surgery, chemotherapy, radiation, and immunotherapy, colorectal cancer (CRC) remains a major clinical challenge, particularly due to the limited efficacy of immune checkpoint inhibitors outside the MSI-H [...] Read more.
Therapeutic vaccines offer a targeted approach to enhancing anti-tumor immunity with minimal systemic toxicity. Despite advancements in surgery, chemotherapy, radiation, and immunotherapy, colorectal cancer (CRC) remains a major clinical challenge, particularly due to the limited efficacy of immune checkpoint inhibitors outside the MSI-H subgroup. In this comprehensive review summarizes the emerging vaccine modalities for CRC, including peptide, nucleic acid, cell-based, vector-driven, and nanotechnology platforms. We discuss the barriers posed by tumor immune evasion and heterogeneity, and highlight innovative strategies designed to improve vaccine efficacy. Finally, we explore recent clinical developments and translational opportunities that position therapeutic vaccines as a promising component of future CRC immunotherapy. Full article
(This article belongs to the Special Issue Cancer Vaccines: 4th Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop